Firms Will Get Heads-Up Before Products Land on FDA's Proposed Drug Watch

Executive Briefing Series

The FDA will alert pharmaceutical companies shortly before their products are placed on the agency’s proposed Drug Watch website for emerging drug-safety concerns, but firms will not be able to appeal or influence the agency’s decisions regarding the site, according to FDA officials.

To View This Article:


Buy This Article Now

Add this article to your cart for $10.00